{"id":112436,"date":"2025-11-10T13:00:56","date_gmt":"2025-11-10T11:00:56","guid":{"rendered":"https:\/\/www.sfee.gr\/?p=112436"},"modified":"2025-11-11T10:18:00","modified_gmt":"2025-11-11T08:18:00","slug":"how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration","status":"publish","type":"post","link":"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/","title":{"rendered":"How do companies that have struck MFN deals see Europe?"},"content":{"rendered":"

The CEOs of three companies have sounded warnings to the region<\/a><\/p>\n

On the pricing policies of countries that will be MFN comparator markets, Albert Bourla of Pfizer said: \u201cWe are hoping that they will understand that they need to change the way that they price their products. Going forward, of course a little bit of help from the US government and USTR trade negotiations also can make that happen. And my assessment is that Howard Lutnick and the US Trade Representatives are finally, finally committed to make this go away.\u201d He cautioned that, if European countries do not offer acceptable reimbursement prices for drugs, \u201cwe will price them to the price that will not affect the US price\u201d\u2014which would presumably mean no public sector coverage.<\/p>\n

David Ricks of Eli Lilly addressed the industry\u2019s concerns about clawbacks in Europe in an interview with The Financial Times. He described the policy as a \u201cone-way insurance system\u201d that will prevent companies from launching new medicines in Europe if it continues. His recommendation was: \u201cLet\u2019s off-ramp this system\u2014it\u2019s well past time\u2014and let\u2019s focus spending on medicines, on things that are breakthroughs, but reward them, and then go through the hard work of compressing budgets in the part of the healthcare systems that are now obsolete because we have breakthroughs and cures.\u201d<\/p>\n

Pascal Soriot of AstraZeneca compared the European commercial environment with those of the United States and China: \u201cIf you look at innovation, it’s happening in the US very rapidly now, it’s happening in China, and there’s not so much in Europe.\u201d Looking ahead, he reflected: \u201cYou still see a large industrial base in Europe, for historical reasons. A problem is future products rely on new technologies that require new manufacturing tools. And these technologies are going to the US, and they\u2019re going to China and other parts of the world, so in 15, 20 years, Europe could easily lose its health sovereignty.\u201d<\/p>\n

Soriot also urged European policymakers to take on a greater share of the risk of drug development: \u201cThe US, for the last number of years, has been really paying for the cost and the risk associated with innovation. We should never forget the risk. Everybody talks about the cost, but there’s a massive risk. I mean, we have a portfolio committee, and very often, we spend several hundred million dollars in one meeting. If those studies fail, it’s a lot of money in the rubbish bin.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

The CEOs of three companies have sounded warnings to the region<\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[429,1257],"tags":[],"class_list":["post-112436","post","type-post","status-publish","format-standard","hentry","category-news","category-miscellaneous","entry"],"acf":[],"yoast_head":"\nHow do companies that have struck MFN deals see Europe? | SFEE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How do companies that have struck MFN deals see Europe? | SFEE\" \/>\n<meta property=\"og:description\" content=\"The CEOs of three companies have sounded warnings to the region\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/\" \/>\n<meta property=\"og:site_name\" content=\"SFEE\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/sfeegreece\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-10T11:00:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-11T08:18:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sfee.gr\/preview.jpg\" \/>\n<meta name=\"author\" content=\"zoe.magklara\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@sfeegreece\" \/>\n<meta name=\"twitter:site\" content=\"@sfeegreece\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"zoe.magklara\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/\"},\"author\":{\"name\":\"zoe.magklara\",\"@id\":\"https:\/\/www.sfee.gr\/en\/#\/schema\/person\/8753cc116d582dae972d12040b60c207\"},\"headline\":\"How do companies that have struck MFN deals see Europe?\",\"datePublished\":\"2025-11-10T11:00:56+00:00\",\"dateModified\":\"2025-11-11T08:18:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/\"},\"wordCount\":426,\"articleSection\":[\"News\",\"Miscellaneous\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/\",\"url\":\"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/\",\"name\":\"How do companies that have struck MFN deals see Europe? | SFEE\",\"isPartOf\":{\"@id\":\"https:\/\/www.sfee.gr\/en\/#website\"},\"datePublished\":\"2025-11-10T11:00:56+00:00\",\"dateModified\":\"2025-11-11T08:18:00+00:00\",\"author\":{\"@id\":\"https:\/\/www.sfee.gr\/en\/#\/schema\/person\/8753cc116d582dae972d12040b60c207\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u0391\u03c1\u03c7\u03b9\u03ba\u03ae\",\"item\":\"https:\/\/www.sfee.gr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How do companies that have struck MFN deals see Europe?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sfee.gr\/en\/#website\",\"url\":\"https:\/\/www.sfee.gr\/en\/\",\"name\":\"\u03a3\u03a6\u0395\u0395\",\"description\":\"The Hellenic Association of Pharmaceutical Companies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.sfee.gr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.sfee.gr\/en\/#\/schema\/person\/8753cc116d582dae972d12040b60c207\",\"name\":\"zoe.magklara\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sfee.gr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d3e3a69f11e65abbdd8cc9708e38f3baae0a6b22516a021ea9557fa235bfb247?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d3e3a69f11e65abbdd8cc9708e38f3baae0a6b22516a021ea9557fa235bfb247?s=96&d=mm&r=g\",\"caption\":\"zoe.magklara\"},\"url\":\"https:\/\/www.sfee.gr\/en\/author\/zoe-magklara\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"How do companies that have struck MFN deals see Europe? | SFEE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/","og_locale":"en_US","og_type":"article","og_title":"How do companies that have struck MFN deals see Europe? | SFEE","og_description":"The CEOs of three companies have sounded warnings to the region","og_url":"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/","og_site_name":"SFEE","article_publisher":"https:\/\/www.facebook.com\/sfeegreece\/","article_published_time":"2025-11-10T11:00:56+00:00","article_modified_time":"2025-11-11T08:18:00+00:00","og_image":[{"url":"https:\/\/www.sfee.gr\/preview.jpg","type":"","width":"","height":""}],"author":"zoe.magklara","twitter_card":"summary_large_image","twitter_creator":"@sfeegreece","twitter_site":"@sfeegreece","twitter_misc":{"Written by":"zoe.magklara","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/#article","isPartOf":{"@id":"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/"},"author":{"name":"zoe.magklara","@id":"https:\/\/www.sfee.gr\/en\/#\/schema\/person\/8753cc116d582dae972d12040b60c207"},"headline":"How do companies that have struck MFN deals see Europe?","datePublished":"2025-11-10T11:00:56+00:00","dateModified":"2025-11-11T08:18:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/"},"wordCount":426,"articleSection":["News","Miscellaneous"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/","url":"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/","name":"How do companies that have struck MFN deals see Europe? | SFEE","isPartOf":{"@id":"https:\/\/www.sfee.gr\/en\/#website"},"datePublished":"2025-11-10T11:00:56+00:00","dateModified":"2025-11-11T08:18:00+00:00","author":{"@id":"https:\/\/www.sfee.gr\/en\/#\/schema\/person\/8753cc116d582dae972d12040b60c207"},"breadcrumb":{"@id":"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sfee.gr\/en\/how-is-the-european-pharmaceutical-market-seen-by-companies-that-have-recently-negotiated-mfn-deals-with-the-trump-administration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u0391\u03c1\u03c7\u03b9\u03ba\u03ae","item":"https:\/\/www.sfee.gr\/en\/"},{"@type":"ListItem","position":2,"name":"How do companies that have struck MFN deals see Europe?"}]},{"@type":"WebSite","@id":"https:\/\/www.sfee.gr\/en\/#website","url":"https:\/\/www.sfee.gr\/en\/","name":"\u03a3\u03a6\u0395\u0395","description":"The Hellenic Association of Pharmaceutical Companies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sfee.gr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.sfee.gr\/en\/#\/schema\/person\/8753cc116d582dae972d12040b60c207","name":"zoe.magklara","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sfee.gr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d3e3a69f11e65abbdd8cc9708e38f3baae0a6b22516a021ea9557fa235bfb247?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d3e3a69f11e65abbdd8cc9708e38f3baae0a6b22516a021ea9557fa235bfb247?s=96&d=mm&r=g","caption":"zoe.magklara"},"url":"https:\/\/www.sfee.gr\/en\/author\/zoe-magklara\/"}]}},"_links":{"self":[{"href":"https:\/\/www.sfee.gr\/en\/wp-json\/wp\/v2\/posts\/112436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sfee.gr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sfee.gr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sfee.gr\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sfee.gr\/en\/wp-json\/wp\/v2\/comments?post=112436"}],"version-history":[{"count":4,"href":"https:\/\/www.sfee.gr\/en\/wp-json\/wp\/v2\/posts\/112436\/revisions"}],"predecessor-version":[{"id":112442,"href":"https:\/\/www.sfee.gr\/en\/wp-json\/wp\/v2\/posts\/112436\/revisions\/112442"}],"wp:attachment":[{"href":"https:\/\/www.sfee.gr\/en\/wp-json\/wp\/v2\/media?parent=112436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sfee.gr\/en\/wp-json\/wp\/v2\/categories?post=112436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sfee.gr\/en\/wp-json\/wp\/v2\/tags?post=112436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}